Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases

The objective of this report is to develop and analyse the commercial proposition of “Respon Therapeutics” in the management of chronic inflammatory skin diseases. “Respon Therapeutics” is a proprietary platform precision drug-delivery system developed by Professor Dang’s Laboratory for the manageme...

Full description

Saved in:
Bibliographic Details
Main Author: Yamini, Prashanth
Other Authors: Dang Thuy Tram
Format: Final Year Project
Language:English
Published: Nanyang Technological University 2024
Subjects:
Online Access:https://hdl.handle.net/10356/177425
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-177425
record_format dspace
spelling sg-ntu-dr.10356-1774252024-05-31T15:32:13Z Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases Yamini, Prashanth Dang Thuy Tram School of Chemistry, Chemical Engineering and Biotechnology TTDang@ntu.edu.sg Business and Management Engineering Medicine, Health and Life Sciences Therapy Psoriasis Eczema The objective of this report is to develop and analyse the commercial proposition of “Respon Therapeutics” in the management of chronic inflammatory skin diseases. “Respon Therapeutics” is a proprietary platform precision drug-delivery system developed by Professor Dang’s Laboratory for the management of chronic inflammatory diseases. It can be customised to suitable indications in this domain, having demonstrated clinical promise and commercial potential in the management of arthritis symptoms. There is now an opportunity to expand it to address symptoms of chronic inflammatory skin diseases such as Eczema and Psoriasis. As a first step, it is imperative to develop and validate some conceptualization of Respon that could address a sufficiently significant and lucrative gap in their current treatment landscapes. There were three key deliverables – gap analysis to identify a significant unsolved problem in the treatment pathway, product-market fit to conceive a format in which Respon could address the identified problem, and market analysis to identify and size the optimal entry market for the proposed solution. Each analysis entailed an iterative and tailored process of literature reviews, secondary market research, primary research (stakeholder interviews), as well as independent and collaborative brainstorming. Ultimately, it was established that the elimination of stubborn psoriatic patches was a significant treatment gap, which could be addressed by intradermal delivery of steroids through a novel “Respon Micro-Array Patch”. This would optimally service 18-35 year-old patients of moderate-severe psoriasis in the United States of America, representing an average annual Beachhead market of $2.03Bn. Bachelor's degree 2024-05-29T01:04:07Z 2024-05-29T01:04:07Z 2024 Final Year Project (FYP) Yamini, P. (2024). Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases. Final Year Project (FYP), Nanyang Technological University, Singapore. https://hdl.handle.net/10356/177425 https://hdl.handle.net/10356/177425 en CBE/23/122 application/pdf Nanyang Technological University
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Business and Management
Engineering
Medicine, Health and Life Sciences
Therapy
Psoriasis
Eczema
spellingShingle Business and Management
Engineering
Medicine, Health and Life Sciences
Therapy
Psoriasis
Eczema
Yamini, Prashanth
Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases
description The objective of this report is to develop and analyse the commercial proposition of “Respon Therapeutics” in the management of chronic inflammatory skin diseases. “Respon Therapeutics” is a proprietary platform precision drug-delivery system developed by Professor Dang’s Laboratory for the management of chronic inflammatory diseases. It can be customised to suitable indications in this domain, having demonstrated clinical promise and commercial potential in the management of arthritis symptoms. There is now an opportunity to expand it to address symptoms of chronic inflammatory skin diseases such as Eczema and Psoriasis. As a first step, it is imperative to develop and validate some conceptualization of Respon that could address a sufficiently significant and lucrative gap in their current treatment landscapes. There were three key deliverables – gap analysis to identify a significant unsolved problem in the treatment pathway, product-market fit to conceive a format in which Respon could address the identified problem, and market analysis to identify and size the optimal entry market for the proposed solution. Each analysis entailed an iterative and tailored process of literature reviews, secondary market research, primary research (stakeholder interviews), as well as independent and collaborative brainstorming. Ultimately, it was established that the elimination of stubborn psoriatic patches was a significant treatment gap, which could be addressed by intradermal delivery of steroids through a novel “Respon Micro-Array Patch”. This would optimally service 18-35 year-old patients of moderate-severe psoriasis in the United States of America, representing an average annual Beachhead market of $2.03Bn.
author2 Dang Thuy Tram
author_facet Dang Thuy Tram
Yamini, Prashanth
format Final Year Project
author Yamini, Prashanth
author_sort Yamini, Prashanth
title Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases
title_short Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases
title_full Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases
title_fullStr Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases
title_full_unstemmed Development of commercial propositions for Respon Therapeutics in the management of chronic skin diseases
title_sort development of commercial propositions for respon therapeutics in the management of chronic skin diseases
publisher Nanyang Technological University
publishDate 2024
url https://hdl.handle.net/10356/177425
_version_ 1800916409957482496